Study Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022 CAR-T cell immunotherapy in relapsed or refractory B-ALL. The investigators plan to include 20 subjects to receive GC022 therapy.
Want to learn more about this trial?
Request More InfoInterventions
GC022BIOLOGICAL
GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Ludaopei Hospital | Sanhe | Hebei | China |